19% Raised

Short Summary

RaySense; Advanced analytics & data modelling platform for healthcare market; Prototype installed in 24+ homes; London NHS Trust & world-renowned research University collaboration; 150+ yrs combined team experience; MVP developed;


Investment Raised
Previous Rounds €220,000
Stage Pre-Startup/R&D
Investor Role Weekly Involvement


  • Large London NHS Trust & world renowned research University collaboration
  • Approved in principle to pilot tech at Harmonia Dementia Village.
  • By 2023 remote patient monitoring is expected to earn more than £24.7 bn.
  • Pressure Ulcers is a global problem £8.7bn causing bed blocking.
  • Mental health expected to cost £12.6 tn globally by 2030 if not addressed
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

Ask a question

Got a question about this project?

Sign up to view the full pitch

It's free to discover the next big thing

Already have an account?

Similar Projects

Global Pro
0% raised

Medics Academy

location_on London, United Kingdom

Imagine training all healthcare professionals a country needs through one system. Pilot with NHS; commercial contracts in place; 2,500+ users in Year 1

€ 1,100,000


€ 1,100

Min per Investor

Global Pro
10% raised

Fertility Innovations Ltd

location_on South West, United Kingdom

FIL has invented & patented the worlds only direct male infertility treatment. Non-invasive, deliverable in primary healthcare facilities, 85%+ effective with sales potential £1.3bn+ pa, set to disrupt & transform the £10bn pa infertility market.

€ 560,000


€ 5,600

Min per Investor

0% raised

Blood Coagulation monitor

location_on W. Midlands, United Kingdom

Bio-AMD have developed a highly sensitive blood coagulation system to measure INR levels of patients after cardiac heart attack, ensure that the patients drug treatment does not lead to clotting or bleed scenario. The system out perform competitors

€ 1,700,000


€ 110

Min per Investor

load one similar proposal